Consistent to the above, in all our cultured NSCLC cell lines, GH treatment enhanced phosphorylation of downstream mediators of GH signaling, including STAT5, STAT3, and AKT, while GHRA (FDA-approved GHR antagonist for acromegaly, pegvisomant [40]) significantly attenuated these effects (Figure 2B,C). Here, GHR is linked to non-small cell lung carcinoma.